VERA logo

VERA THERAPEUTICS INC

VERANASDAQ
🏆 #1885 by market capEarnings Nov 3US Equity
$718.97▼ $24.73 (−3.44%)
Simulated price
🔔
Track VERA
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 3.4%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$2.32B
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
68
Fair
No chart data available for VERA.

Trading Snapshot

Day Range
$709.44 – $725.53
52-Week Range
$23.05 – $56.05
Volume
$2.90B
Avg Volume
$2.80B
Shares Outstanding
71.8M
Next Earnings
Nov 23, 2026

Fundamentals Snapshot

Annual Revenue
$553M
Last Q Revenue
$135M
P/E Ratio
-5.5
P/S Ratio
0.0x
EPS (TTM)
$-5.59
Dividend Yield
0.00%
Dilution (1yr)
+17.0%

Why Investors Own VERA

  • ✓High-growth profile — revenue up +10.1% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 47% gross margin and 8% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

VERA logo

VERA THERAPEUTICS INC

VERA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$315M▲ +88.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$242M▲ +78.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
64.2M▲ +17.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$277M▲ +$239M YoY
StockOtter · stockotter.space

About VERA THERAPEUTICS INC

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Price Target

ⓘ
Average Target
$945.62
▲ +31.5% Upside
High Target$1,097.68
Low Target$854.53
Based on 18 analysts

Latest News & Updates

🚀
Barron’s·2h ago

VERA THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift VERA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

VERA THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.